Perspectives in melanoma: meeting report from the “Melanoma Bridge” (December 5th–7th, 2019, Naples, Italy)
Abstract The melanoma treatment landscape changed in 2011 with the approval of the first anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 checkpoint inhibitor and of the first BRAF-targeted monoclonal antibody, both of which significantly improved overall survival (OS). Since then, improved u...
| Hoofdauteurs: | , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formaat: | Artikel |
| Taal: | English |
| Gepubliceerd in: |
BMC
2020-09-01
|
| Reeks: | Journal of Translational Medicine |
| Onderwerpen: | |
| Online toegang: | http://link.springer.com/article/10.1186/s12967-020-02482-x |
| _version_ | 1828482277984698368 |
|---|---|
| author | Paolo A. Ascierto Igor Puzanov Sanjiv S. Agarwala Christian Blank Richard D. Carvajal Sandra Demaria Reinhard Dummer Marc Ernstoff Soldano Ferrone Bernard A. Fox Thomas F. Gajewski Claus Garbe Patrick Hwu Roger S. Lo Georgina V. Long Jason J. Luke Iman Osman Michael A. Postow Ryan J. Sullivan Janis M. Taube Giorgio Trinchieri Hassane M. Zarour Corrado Caracò Magdalena Thurin |
| author_facet | Paolo A. Ascierto Igor Puzanov Sanjiv S. Agarwala Christian Blank Richard D. Carvajal Sandra Demaria Reinhard Dummer Marc Ernstoff Soldano Ferrone Bernard A. Fox Thomas F. Gajewski Claus Garbe Patrick Hwu Roger S. Lo Georgina V. Long Jason J. Luke Iman Osman Michael A. Postow Ryan J. Sullivan Janis M. Taube Giorgio Trinchieri Hassane M. Zarour Corrado Caracò Magdalena Thurin |
| author_sort | Paolo A. Ascierto |
| collection | DOAJ |
| description | Abstract The melanoma treatment landscape changed in 2011 with the approval of the first anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 checkpoint inhibitor and of the first BRAF-targeted monoclonal antibody, both of which significantly improved overall survival (OS). Since then, improved understanding of the tumor microenvironment (TME) and tumor immune-evasion mechanisms has resulted in new approaches to targeting and harnessing the host immune response. The approval of new immune and targeted therapies has further improved outcomes for patients with advanced melanoma and other combination modalities are also being explored such as chemotherapy, radiotherapy, electrochemotherapy and surgery. In addition, different strategies of drugs administration including sequential or combination treatment are being tested. Approaches to overcome resistance and to potentiate the immune response are being developed. Increasing evidence emerges that tissue and blood-based biomarkers can predict the response to a therapy. The latest findings in melanoma research, including insights into the tumor microenvironment and new biomarkers, improved understanding of tumor immune response and resistance, novel approaches for combination strategies and the role of neoadjuvant and adjuvant therapy, were the focus of discussions at the Melanoma Bridge meeting (5–7 December, 2019, Naples, Italy), which are summarized in this report. |
| first_indexed | 2024-12-11T08:11:33Z |
| format | Article |
| id | doaj.art-f2b099b821ea4c5eaa13a1fff3485d97 |
| institution | Directory Open Access Journal |
| issn | 1479-5876 |
| language | English |
| last_indexed | 2024-12-11T08:11:33Z |
| publishDate | 2020-09-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Translational Medicine |
| spelling | doaj.art-f2b099b821ea4c5eaa13a1fff3485d972022-12-22T01:14:52ZengBMCJournal of Translational Medicine1479-58762020-09-0118112210.1186/s12967-020-02482-xPerspectives in melanoma: meeting report from the “Melanoma Bridge” (December 5th–7th, 2019, Naples, Italy)Paolo A. Ascierto0Igor Puzanov1Sanjiv S. Agarwala2Christian Blank3Richard D. Carvajal4Sandra Demaria5Reinhard Dummer6Marc Ernstoff7Soldano Ferrone8Bernard A. Fox9Thomas F. Gajewski10Claus Garbe11Patrick Hwu12Roger S. Lo13Georgina V. Long14Jason J. Luke15Iman Osman16Michael A. Postow17Ryan J. Sullivan18Janis M. Taube19Giorgio Trinchieri20Hassane M. Zarour21Corrado Caracò22Magdalena Thurin23Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”Roswell Park Comprehensive Cancer CenterTemple University School of MedicineNetherlands Cancer InstituteColumbia University Irving Medical Center, Herbert Irving Comprehensive Cancer CenterDepartment of Radiation Oncology, Weill Cornell MedicineDepartment of Dermatology, University of Zurich HospitalRoswell Park Comprehensive Cancer Center, Jacobs School of Medicine and Biomedical Sciences, State UniversityDepartment of Surgery, Massachusetts General Hospital, Harvard Medical SchoolEarle A. Chiles Research Institute, Robert W. Franz Cancer Research Center, Providence Cancer InstituteDepartment of Pathology, University of ChicagoCenter for Dermatooncology, Department of Dermatology, Eberhard Karls UniversityDepartment of Melanoma Medical Oncology, Division of Cancer Medicine, Anderson Cancer CenterJonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLAMelanoma Institute Australia, The University of Sydney and Royal North Shore and Mater HospitalsMedicine University of ChicagoThe Interdisciplinary Melanoma Program, New York University Langone Medical Center, NYU Grossman Medical SchoolMemorial Sloan Kettering Cancer Center and Weill Cornell Medical CollegeMelanoma Program, Mass General Cancer CenterDivision of Dermatopathology, Johns Hopkins University School of MedicineLaboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, National Institutes of HealthHillman Cancer Center, University of PittsburghDepartment Melanoma, Soft Tissue, Muscle-Skeletal and Head-Neck, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”Cancer Diagnosis Program, Division of Cancer Treatment and Diagnosis, NCIAbstract The melanoma treatment landscape changed in 2011 with the approval of the first anti-cytotoxic T-lymphocyte-associated protein (CTLA)-4 checkpoint inhibitor and of the first BRAF-targeted monoclonal antibody, both of which significantly improved overall survival (OS). Since then, improved understanding of the tumor microenvironment (TME) and tumor immune-evasion mechanisms has resulted in new approaches to targeting and harnessing the host immune response. The approval of new immune and targeted therapies has further improved outcomes for patients with advanced melanoma and other combination modalities are also being explored such as chemotherapy, radiotherapy, electrochemotherapy and surgery. In addition, different strategies of drugs administration including sequential or combination treatment are being tested. Approaches to overcome resistance and to potentiate the immune response are being developed. Increasing evidence emerges that tissue and blood-based biomarkers can predict the response to a therapy. The latest findings in melanoma research, including insights into the tumor microenvironment and new biomarkers, improved understanding of tumor immune response and resistance, novel approaches for combination strategies and the role of neoadjuvant and adjuvant therapy, were the focus of discussions at the Melanoma Bridge meeting (5–7 December, 2019, Naples, Italy), which are summarized in this report.http://link.springer.com/article/10.1186/s12967-020-02482-xMelanomaImmunotherapyAnti-PD-1Anti-CTLA-4Target therapyBiomarkers |
| spellingShingle | Paolo A. Ascierto Igor Puzanov Sanjiv S. Agarwala Christian Blank Richard D. Carvajal Sandra Demaria Reinhard Dummer Marc Ernstoff Soldano Ferrone Bernard A. Fox Thomas F. Gajewski Claus Garbe Patrick Hwu Roger S. Lo Georgina V. Long Jason J. Luke Iman Osman Michael A. Postow Ryan J. Sullivan Janis M. Taube Giorgio Trinchieri Hassane M. Zarour Corrado Caracò Magdalena Thurin Perspectives in melanoma: meeting report from the “Melanoma Bridge” (December 5th–7th, 2019, Naples, Italy) Journal of Translational Medicine Melanoma Immunotherapy Anti-PD-1 Anti-CTLA-4 Target therapy Biomarkers |
| title | Perspectives in melanoma: meeting report from the “Melanoma Bridge” (December 5th–7th, 2019, Naples, Italy) |
| title_full | Perspectives in melanoma: meeting report from the “Melanoma Bridge” (December 5th–7th, 2019, Naples, Italy) |
| title_fullStr | Perspectives in melanoma: meeting report from the “Melanoma Bridge” (December 5th–7th, 2019, Naples, Italy) |
| title_full_unstemmed | Perspectives in melanoma: meeting report from the “Melanoma Bridge” (December 5th–7th, 2019, Naples, Italy) |
| title_short | Perspectives in melanoma: meeting report from the “Melanoma Bridge” (December 5th–7th, 2019, Naples, Italy) |
| title_sort | perspectives in melanoma meeting report from the melanoma bridge december 5th 7th 2019 naples italy |
| topic | Melanoma Immunotherapy Anti-PD-1 Anti-CTLA-4 Target therapy Biomarkers |
| url | http://link.springer.com/article/10.1186/s12967-020-02482-x |
| work_keys_str_mv | AT paoloaascierto perspectivesinmelanomameetingreportfromthemelanomabridgedecember5th7th2019naplesitaly AT igorpuzanov perspectivesinmelanomameetingreportfromthemelanomabridgedecember5th7th2019naplesitaly AT sanjivsagarwala perspectivesinmelanomameetingreportfromthemelanomabridgedecember5th7th2019naplesitaly AT christianblank perspectivesinmelanomameetingreportfromthemelanomabridgedecember5th7th2019naplesitaly AT richarddcarvajal perspectivesinmelanomameetingreportfromthemelanomabridgedecember5th7th2019naplesitaly AT sandrademaria perspectivesinmelanomameetingreportfromthemelanomabridgedecember5th7th2019naplesitaly AT reinharddummer perspectivesinmelanomameetingreportfromthemelanomabridgedecember5th7th2019naplesitaly AT marcernstoff perspectivesinmelanomameetingreportfromthemelanomabridgedecember5th7th2019naplesitaly AT soldanoferrone perspectivesinmelanomameetingreportfromthemelanomabridgedecember5th7th2019naplesitaly AT bernardafox perspectivesinmelanomameetingreportfromthemelanomabridgedecember5th7th2019naplesitaly AT thomasfgajewski perspectivesinmelanomameetingreportfromthemelanomabridgedecember5th7th2019naplesitaly AT clausgarbe perspectivesinmelanomameetingreportfromthemelanomabridgedecember5th7th2019naplesitaly AT patrickhwu perspectivesinmelanomameetingreportfromthemelanomabridgedecember5th7th2019naplesitaly AT rogerslo perspectivesinmelanomameetingreportfromthemelanomabridgedecember5th7th2019naplesitaly AT georginavlong perspectivesinmelanomameetingreportfromthemelanomabridgedecember5th7th2019naplesitaly AT jasonjluke perspectivesinmelanomameetingreportfromthemelanomabridgedecember5th7th2019naplesitaly AT imanosman perspectivesinmelanomameetingreportfromthemelanomabridgedecember5th7th2019naplesitaly AT michaelapostow perspectivesinmelanomameetingreportfromthemelanomabridgedecember5th7th2019naplesitaly AT ryanjsullivan perspectivesinmelanomameetingreportfromthemelanomabridgedecember5th7th2019naplesitaly AT janismtaube perspectivesinmelanomameetingreportfromthemelanomabridgedecember5th7th2019naplesitaly AT giorgiotrinchieri perspectivesinmelanomameetingreportfromthemelanomabridgedecember5th7th2019naplesitaly AT hassanemzarour perspectivesinmelanomameetingreportfromthemelanomabridgedecember5th7th2019naplesitaly AT corradocaraco perspectivesinmelanomameetingreportfromthemelanomabridgedecember5th7th2019naplesitaly AT magdalenathurin perspectivesinmelanomameetingreportfromthemelanomabridgedecember5th7th2019naplesitaly |